Support and Resistance Levels
Past performance
About Aptus Pharma Ltd Aptus Pharma Limited, originally established as Aptus Pharma Private Limited in August 2010, is a pharmaceutical company headquartered in Gujarat, India. The company transitioned to a public limited entity in December 2024. It operates in the pharmaceutical marketing and distribution space, relying on a contract manufacturing model through seven partner manufacturing units. Aptus Pharma offers a diverse product portfolio spanning multiple therapeutic categories, including anti-infectives, gastrointestinal remedies, pain management, cardiovascular and antidiabetic medicines, as well as general wellness products. These are available in varied dosage forms such as tablets, capsules, syrups, and injections.
Since its inception, Aptus Pharma has steadily expanded its product range, starting with 25 offerings in 2013 and growing to over 175 products by 2024. The company's operations are divided into three segments: Acute, Chronic, and OTC (over-the-counter). This segmentation allows Aptus Pharma to cater to both acute and chronic ailments while also offering general wellness solutions. Its product portfolio targets essential therapeutic needs, serving a broad spectrum of both acute and chronic healthcare requirements.
Aptus Pharma's regional operations began with headquarters in Gujarat, and over the years, the company has successfully expanded its reach and offerings. The company is now poised for a significant growth milestone, with plans to launch an Initial Public Offering (IPO) of 20,00,000 equity shares with a face value of Rs. 10 each through a fresh issue. Aptus Pharma's consistent growth, diversified portfolio, and strategic push toward public listing highlight its ambition to capitalize on opportunities in the pharmaceutical market, making it an attractive consideration for potential investors and traders.